News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
685,578 Results
Type
Article (39053)
Company Profile (279)
Press Release (646246)
Section
Business (203872)
Career Advice (1991)
Deals (35363)
Drug Delivery (85)
Drug Development (80800)
Employer Resources (168)
FDA (16086)
Job Trends (14805)
News (344550)
Policy (32436)
Tag
Academia (2530)
Alliances (49089)
Alzheimer's disease (1229)
Approvals (16018)
Artificial intelligence (130)
Bankruptcy (352)
Best Places to Work (11534)
Biotechnology (200)
Breast cancer (120)
Cancer (1081)
Cardiovascular disease (97)
Career advice (1660)
Cell therapy (232)
Clinical research (64241)
Collaboration (387)
Compensation (197)
COVID-19 (2530)
C-suite (94)
Data (1119)
Diabetes (152)
Diagnostics (6138)
Earnings (84817)
Employer resources (146)
Events (109472)
Executive appointments (310)
FDA (16621)
Funding (349)
Gene therapy (177)
GLP-1 (575)
Government (4325)
Healthcare (18669)
Infectious disease (2615)
Inflammatory bowel disease (106)
Interviews (308)
IPO (16297)
Job creations (3624)
Job search strategy (1417)
Layoffs (412)
Legal (7853)
Lung cancer (170)
Manufacturing (176)
Medical device (13174)
Medtech (13179)
Mergers & acquisitions (19141)
Metabolic disorders (401)
Neuroscience (1504)
NextGen Class of 2024 (6499)
Non-profit (4464)
Northern California (1476)
Obesity (231)
Opinion (180)
Patents (102)
People (56275)
Phase I (19952)
Phase II (28299)
Phase III (21095)
Pipeline (455)
Postmarket research (2553)
Preclinical (8492)
Radiopharmaceuticals (236)
Rare diseases (218)
Real estate (5890)
Regulatory (21517)
Research institute (2309)
Resumes & cover letters (349)
Southern California (1298)
Startups (3562)
United States (13446)
Vaccines (548)
Weight loss (167)
Date
Today (133)
Last 7 days (763)
Last 30 days (3778)
Last 365 days (35623)
2024 (32678)
2023 (40075)
2022 (51175)
2021 (55713)
2020 (54087)
2019 (46541)
2018 (35019)
2017 (32110)
2016 (31480)
2015 (37553)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (192)
Asia (37118)
Australia (6057)
California (3318)
Canada (1289)
China (247)
Colorado (144)
Connecticut (152)
Europe (79502)
Florida (458)
Georgia (116)
Illinois (341)
Indiana (196)
Kansas (96)
Maryland (575)
Massachusetts (2603)
Michigan (157)
Minnesota (272)
New Jersey (952)
New York (957)
North Carolina (701)
Northern California (1476)
Ohio (139)
Pennsylvania (843)
South America (1091)
Southern California (1298)
Texas (461)
Utah (90)
Washington State (360)
685,578 Results for "zymeworks inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Zymeworks Announces Participation in Upcoming Investor Conferences
October 29, 2024
·
3 min read
Zymeworks Announces Participation in Upcoming June 2024 Investor Conferences
Zymeworks Inc., a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, announced that management will participate in the following upcoming investor conferences.
May 28, 2024
·
2 min read
Zymeworks Announces Participation in Upcoming May 2024 Investor Conferences
Zymeworks Inc., a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, announced that management will participate in the following upcoming investor conferences.
April 30, 2024
·
2 min read
Press Releases
Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results
November 1, 2024
·
20 min read
Business
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
Zymeworks Inc. announced the appointment of Dr. Neil Gallagher to its board of directors effective April 2, 2024.
March 28, 2024
·
6 min read
Zymeworks Announces Participation in Upcoming April 2024 Investor Conferences
Zymeworks Inc., a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, announced that management will participate in the following upcoming investor conferences.
March 27, 2024
·
2 min read
Business
Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
Zymeworks Inc. announced that management will report its first quarter 2024 financial results after market close on May 2, 2024.
April 11, 2024
·
2 min read
Policy
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
Zymeworks Inc. announced that the United States Food and Drug Administration has cleared the investigational new drug application for ZW171, a novel 2+1 T-cell targeting bispecific antibody for mesothelin -expressing cancers.
June 17, 2024
·
7 min read
Business
Zymeworks Announces Additional Leadership Appointments
Zymeworks Inc. today announced significant additions to its leadership team.
January 4, 2024
·
6 min read
Policy
Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
Zymeworks Inc., a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, announced that the Center for Drug Evaluation of the National Medical Products Administration in China has accepted the BLA for zanidatamab for second-line treatment of HER2-positive BTC.
June 10, 2024
·
12 min read
1 of 68,558
Next
